The optimal duration of induction therapy (IT) in transplant-eligible multiple myeloma (MM) patients in not well defined, resulting in a wide variation in clinical practice. The objective of our study was to determine whether the duration of IT in patients undergoing upfront autologous stem cell transplantation (ASCT) has an impact on progression-free survival (PFS) in the era of proteasome inhibitors and immunomodulatory drugs. A total of 596 patients who underwent ASCT at Mayo Clinic between 2007 and 2014 were included. The patients were divided into two cohorts based on the duration of IT: IT ≤ 4 and IT > 4 months. At a median follow-up of 54Á5 months from ASCT, the median PFS in the IT ≤ 4 group was 28 months [95% confidence interval (CI), 25-33], compared to 26 months in the IT > 4 group (95% CI, 24-31) [P = 0Á605]. There was no significant difference in overall survival (OS) in the two groups (P = 0Á904). The lack of impact of IT duration on PFS and OS was consistent in subgroups with high-risk features at diagnosis (International Staging System III or high-risk cytogenetics) and different depths of pre-transplant response [≥very good partial response (VGPR) and <VGPR]. In conclusion, prolonging the duration of IT beyond 4 months does not impact survival in patients with newly diagnosed MM who complete a single line of IT followed by consolidation with ASCT.
Summary
The optimal duration of induction therapy (IT) in transplant-eligible multiple myeloma (MM) patients in not well defined, resulting in a wide variation in clinical practice. The objective of our study was to determine whether the duration of IT in patients undergoing upfront autologous stem cell transplantation (ASCT) has an impact on progression-free survival (PFS) in the era of proteasome inhibitors and immunomodulatory drugs. A total of 596 patients who underwent ASCT at Mayo Clinic between 2007 and 2014 were included. The patients were divided into two cohorts based on the duration of IT: IT ≤ 4 and IT > 4 months. At a median follow-up of 54Á5 months from ASCT, the median PFS in the IT ≤ 4 group was 28 months [95% confidence interval (CI), [25] [26] [27] [28] [29] [30] [31] [32] [33] , compared to 26 months in the IT > 4 group (95% CI, 24-31) [P = 0Á605]. There was no significant difference in overall survival (OS) in the two groups (P = 0Á904). The lack of impact of IT duration on PFS and OS was consistent in subgroups with high-risk features at diagnosis (International Staging System III or high-risk cytogenetics) and different depths of pre-transplant response [≥very good partial response (VGPR) and <VGPR]. In conclusion, prolonging the duration of IT beyond 4 months does not impact survival in patients with newly diagnosed MM who complete a single line of IT followed by consolidation with ASCT.
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The overall survival (OS) in patients with multiple myeloma (MM) has increased in the last decade due to the introduction of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs) and monoclonal antibodies as well as a wider incorporation of autologous stem cell transplantation (ASCT) for eligible patients (Schaapveld et al, 2010; Kumar et al, 2014; Fonseca et al, 2017) . Three-drug regimens, including a PI and an IMiD, have become the standard of care for induction therapy (IT) in both transplant-eligible (TE) and non-TE patients in recent years (Kumar et al, 2017) . Most guidelines recommend 4-6 cycles of IT prior to ASCT in TE patients (Moreau et al, 2015 . However, to the best of our knowledge, there is a lack of data on comparative outcomes of different durations of IT prior to ASCT in newly diagnosed MM. In clinical practice, IT is usually continued until a deep response or a plateau is achieved. Achievement of a very good partial response (VGPR) or better after IT was associated with a superior progression-free survival (PFS) in patients receiving upfront ASCT in the Intergroupe Francophone du My elome (IFM) 2005-01 trial (Moreau et al, 2011) . However, in the current treatment paradigm of continuous therapy in MM and availability of multiple salvage regimens at relapse, it is unclear whether the depth of pre-transplant response and duration of IT prior to ASCT has an impact on time to disease progression and survival. Studies have shown that posttransplant depth of response is prognostically more important than pre-transplant response in determining long-term outcomes in the era of PIs and IMiDs (Kapoor et al, 2013) .
With the routine use of triplets containing PIs and IMiDs for IT in all newly diagnosed TE-MM patients and post-transplant maintenance with lenalidomide until progression, the cost of MM therapy has increased sharply . Furthermore, due to a lack of evidence of benefit of longer durations of IT prior to ASCT from prospective trials, it is unclear whether prolonging IT beyond 3-4 months in patients responding to treatment confers any benefit in terms of PFS or OS. Given that PIs and IMiDs are associated with significant toxicities, including peripheral neuropathy (Delforge & Ludwig, 2017) , unnecessary prolongation of IT in TE patients should be avoided, if it does not impact long-term outcomes. The objective of our study was to determine whether the duration of induction therapy prior to ASCT has an impact on PFS after transplant in the current era.
Methods

Patients
This study was approved by the Mayo Clinic Institutional Review Board and was conducted in accordance with federal regulations and the principles of the Declaration of Helsinki. Informed consent was obtained from all patients. We have included all consecutive patients who underwent upfront ASCT (<12 months from diagnosis) at Mayo Clinic between 1 January 2007 to 31 December 2014 after receiving PI and/or IMiD-based induction therapy. This time period was chosen due to the routine use of PIs and IMiDs for induction therapy and availability of multiple novel agents at relapse. Exclusion criteria included use of more than one line of induction therapy prior to ASCT, one or more relapse prior to ASCT and use of an induction regimen without a PI or an IMiD.
The exact duration of induction regimen (including day and month) was available for 420 (71%) patients. For patients in whom only the start and end months were available (n = 174; 29%), we have included the whole month while calculating the induction duration. Patients were classified as having high-risk cytogenetics by fluorescence in situ hybridisation (FISH) if they had del(17p), t(4;14), t(14;20), t(14;16) or +1q at diagnosis or at first presentation to Mayo Clinic prior to ASCT. Stem cell mobilization, conditioning regimens and transplant management in Mayo Clinic has been previously described (Gertz et al, 2008; . Response was determined according to the current International Myeloma Working Group response criteria (Kumar et al, 2016) . The primary end-point of the study was PFS from ASCT. The secondary end-points were post-transplant response and overall survival (OS). PFS was defined as time from ASCT to disease progression or death due to any cause. OS was defined as time from ASCT to death due to any cause. Patients who were alive and free of disease were censored at the last follow-up visit.
Statistical analysis
The two-sided Fisher's exact test was used to test for differences between categorical variables. Two-sided Wilcoxon rank-sum test was used to test for differences between continuous variables. Survival analysis was done using the method described by Kaplan and Meier (1958) . Statistical analysis was performed using the JMP 10.0.0 statistical package (SAS Institute Inc., Cary, NC). A P-value of less than 0Á05 was used to define statistical significance.
Results
A total of 596 patients met the eligibility criteria and were included in the analysis. A CONSORT diagram depicting Median induction duration (range), months
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18 (11) 11 (7) 0Á124 VRd 110 (18) 34 (24) 25 ( patient selection is shown in Fig 1. The median duration of IT in the entire cohort was 3Á98 months (range, 1Á35-9Á63), with a median time from diagnosis to transplant being 5Á9 months (range, 2Á3-11Á8). The most common induction regimens used were lenalidomide-dexamethasone (Rd; 35%), bortezomib-dexamethasone (Vd; 10%), bortezomib-lenalidomide-dexamethasone (VRd; 18%) and cyclophosphamidebortezomib-dexamethasone (VCd; 29%). Twenty-three per cent of patients were classified as International Staging System (ISS) stage 3 at diagnosis and high-risk FISH cytogenetics was present in 21% of patients. A total of 202 (34%) patients had received planned post-transplant maintenance therapy starting on day 100 after ASCT. The baseline characteristics of the entire cohort are shown in Table I . The median follow-up for the entire cohort was 54Á5 months [95% confidence interval (CI), 49Á4-58Á0]. A total of 429 events (progression or death) had occurred at the time of data analysis, including 153 deaths. First, we evaluated the impact of duration of IT (as a continuous variable) on PFS (primary end-point) using the Cox model. There was no significant impact of increasing duration of IT on PFS from ASCT [univariate hazard ratio (HR) 0Á89, 95% CI, 0Á51-1Á52; P = 0Á664]. Subsequently, we stratified the entire cohort into two subgroups based on the duration of IT (≤4 or >4 months), which resulted in two roughly equal-size cohorts for comparison. The median duration of IT in the IT ≤ 4 group (n = 303; 51%) was 3Á4 months (range, 1Á34-3Á98) and that in the IT > 4 group (n = 293; 49%) was 5 months (range, 4Á01-9Á62). The median PFS in patients receiving IT for ≤4 months was 28 months (95% CI, 25-33), compared to 26 months for those receiving >4 months of IT (95% CI, 24-31) [P = 0Á605]. The rate of pre-transplant ≥VGPR (47Á5% vs. 42% respectively), partial response (PR) [41% vs. 46% respectively] and <PR [12% vs. 11% respectively] was similar in the two groups (P = 0Á795). The posttransplant stringent complete response (sCR) rate in the two respective groups was 32Á3% and 38Á6% (P = 0Á112). There was no significant difference in OS in the two groups (5-year OS rate, 74% vs. 72% respectively; P = 0Á904). The Kaplan Meier curves for PFS and OS is shown in Fig 2A, B .
Given that the duration of IT in clinical practice is often determined by the depth and dynamics of serologic response, we divided the patients into two subgroups based on the depth of response achieved prior to transplant: patients with a VGPR or better (≥VGPR group; n = 268; 45%) and those with less than a VGPR (<VGPR group; n = 328; 55%). The median duration of induction therapy in the ≥VGPR group was 3Á9 months (range, 1Á8-9Á6) and in the <VGPR group was 4Á0 months (range, 1Á3-9Á5) [P = 0Á07]. Subsequently, we stratified the ≥VGPR and <VGPR groups into two subgroups each, based on the duration of induction therapy prior to ASCT: IT ≤ 4 months and IT > 4 months. The baseline characteristics of the four subgroups are given in Table I . The groups were well balanced with respect to age at diagnosis, ISS stage and incidence of high-risk cytogenetics by FISH. There were no significant differences in the frequency of use of different induction regimens among the four subgroups. Data on primary and secondary endpoints are shown in Table II . In the group with ≥VGPR at transplant, IT > 4 months led to a higher rate of post-transplant sCR compared to IT ≤ 4 months (sCR rate 64% vs. 52% respectively; P = 0Á054). However, it did not translate into a superior PFS or OS (median PFS, 31 months in IT > 4 vs. 32 months in IT ≤ 4 subgroups; P = 0Á067 and 5-year OS rate 67% and 69% respectively; P = 0Á874). Similarly, in the group with <VGPR at transplant, no significant difference in post-transplant sCR rate, PFS or OS was noted between the subgroups receiving different durations of IT (P-value 0Á533 and 0Á908 for PFS and OS respectively). The Kaplan-Meier curves for PFS stratified by the duration of IT in the ≥VGPR and <VGPR groups are shown in Fig 3. We explored whether a longer duration of induction therapy is beneficial in patients with high-risk features, including ISS stage III or high-risk FISH cytogenetics or both. A total of 238 patients had ISS stage III or high-risk FISH cytogenetics or both at diagnosis, among which 125 patients (53%) were in VGPR or better prior to transplant. There was no significant difference in PFS in this high-risk subgroup among patients receiving ≤4 or >4 months of IT (median PFS, 25 months vs. 24 months respectively; P = 0Á659).
Discussion
Our study shows that in patients with newly diagnosed MM undergoing upfront ASCT, IT duration of up to 4 months leads to similar post-transplant outcomes compared to more than 4 months of IT. The duration of IT did not seem to influence PFS from transplant in subgroups of patients with high-risk disease at diagnosis, including those with ISS stage III, high-risk FISH cytogenetics or both. Although the rate of post-transplant sCR was marginally higher in the IT > 4 compared to IT ≤ 4 group, the difference was not statistically significant.
The optimal duration of IT and depth of pre-transplant response in TE newly diagnosed MM remains uncertain, resulting in a wide variation of clinical practice. Randomized clinical trials comparing frontline to delayed ASCT in the era of PIs and IMiDs typically use 3-4 cycles of IT before single or tandem ASCT (Palumbo et al, 2014; Attal et al, 2017) . However, as evident in our study, the duration of induction therapy varied from 1Á3 to 9Á6 months, which probably represents the real world practice in the United States given that et al, 2017) . Furthermore, the use of VRd as a pre-transplant induction regimen has also increased, from 19% to 58%, during the respective time periods. With the increasing use of highly effective novel agent-based induction regimens, it is anticipated that the majority of patients will go into transplant in a deep response. The duration of IT did not determine post-transplant PFS or OS in the subgroup of patients achieving VGPR or better prior to ASCT in our study. This probably indicates that TE patients achieving an early and deep response can safely proceed to ASCT after 2-4 months of IT, which was the duration for our cohort in the IT ≤ 4 group. However, it is unclear from our study whether patients who went into ASCT in less than a VGPR after IT of 4 months or less duration would have benefited from administration of further therapy in the uncertain hope that it might improve their depth of response prior to ASCT. An observational study using the Center for International Blood and Marrow Transplant Research (CIBMTR) database has shown that in TE patients achieving less than a PR to first-line induction therapy, administration of a salvage "second-line" IT prior to ASCT leads to an improvement in the depth of pre-transplant response but does not have any impact on PFS or OS (Vij et al, 2015) . Although the CIBMTR study included predominantly patients treated prior to the era of PIs and IMiDs, it demonstrated that delaying ASCT in patients achieving a suboptimal response to IT does not improve survival. At the beginning of the era of stem cell transplantation for MM, the selection of four cycles of induction therapy was not evidence-based. In many instances, 4 months of induction was selected simply to allow insurance approval in the United States and in the hope that a lower tumour mass would result in better outcomes although this was never proven.
This study has limitations. Being retrospective in nature, there is a possibility of selection bias because only patients who were deemed eligible for upfront ASCT after successfully completing a single line of IT were included. The dynamics of serological response were not available, which might be a better determinant of the duration of IT. Furthermore, only about one-third of patients received planned post-transplant maintenance therapy. However, all patients in our study had received PI and/or IMiD-based induction, including triplet regimens in almost 50% of patients, which reflects contemporary practice. To our knowledge, this is the first study to assess the impact of duration of pre-transplant IT on post-transplant progression and survival in the current era. However, well-designed prospective studies are needed comparing different durations of IT prior to ASCT to validate these findings and identify the optimal duration of IT and depth of pre-transplant response. Given that longer duration of IT can lead to increased cumulative adverse effects, impact on health-related quality of life should also be assessed in future studies. 
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